EZZ Life Science Holdings

US Rebranding And New Product Launches Will Broaden Global Reach

AnalystConsensusTarget

Not Invested

Consensus Narrative from 1 Analyst

Published

24 Apr 25

Updated

15 Aug 25

AnalystConsensusTarget's Fair Value

AU$5.00

50.6% undervalued

15 Aug

AU$2.47

26.7%

1.2%

26.7%

1.2%

Author's Valuation

AU$5.0

50.6% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates1

Shared on01 May 25

AnalystConsensusTarget Fair Value

AU$5.0

50.6% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

14.87%

Life Sciences revenue growth rate

0.33%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.81%

Calculation

AU$11.96m

Earnings '28

28.53x

PE Ratio '28

AU$341.21m

Market Cap '28

AU$341.21m

Market Cap '28

56.53m

No. shares '28

AU$6.04

Share Price '28

AU$6.04 Share Price '28

Discounted to 2025 @ 6.81% p.a.

AU$4.95

Fair Value '25